MIAMI, FL–( EMWNews – April 2, 2008) – Wall Street Press Wire

(www.WallStreetPressWire.com) is pleased to highlight its “stocks on the

move” for Tuesday. Our list includes: Oncolin Therapeutics (OTCBB: OCOL),

Cell Genesys, Inc. (NASDAQ: CEGE), InterMune, Inc. (NASDAQ: ITMN) and

Lehman Brothers Holdings Inc. (NYSE: LEH).

Having just received an intermediate term price target of $1.45, Wall

Street Press Wire is initiating its in-depth coverage of Oncolin

Therapeutics (OTCBB: OCOL), a biopharmaceutical company that engages in the

discovery, development and commercialization of novel selective anticancer

therapies.

Tuesday after the markets closed, the company issued an important press

release announcing that it has obtained an exclusive worldwide right to

option patents covering the composition and use of Genistein analogs for

cancer treatment.

This news should be welcomed by the company and its investors! The

technology was discovered and patented by the Pharmaceutical Research

Institute of Warsaw Poland and involves compounds that appear to be novel

antimicrotubule agents. Given the widespread success of antimicrotubule

therapies in curative and palliative cancer treatment, the microtubule is

perhaps the single best cancer target identified to date and continues to

be recognized as a strategic target against which to direct new development

efforts.

The approved drugs from this mechanistic class include the Vinca alkaloids

such as vincristine, the taxanes with paclitaxel and docetaxel and the

epothilones with its first drug recently approved by Bristol Myers. Each of

these different types of compound classes appear to interact at different

parts of the microtubule and have different spectrums of activity and show

effectiveness against resistant disease.

“We are happy to have obtained this exclusive agreement on what may be

another unique antimicrotubule class of compounds. We will work closely

with both the Pharmaceutical Research Institute of Warsaw Poland and the

MD Anderson Cancer Center to further evaluate the compounds anticancer

activity to continue to advance a lead compound into clinical

development,” said Dr. Donald Picker, President and COO of the company.

Other recent news that should be of interest of investors includes:

Oncolin Announces Its Research Program Receives Peer Reviewed National

Institute of Health Grant of $179,000.

Oncolin has recently announced it has obtained an exclusive option

agreement with The University of Texas M.D. Anderson Cancer Center which

provides the Company the right to negotiate a license for five technologies

relating to the treatment of various cancers over a nine month period.

Oncolin has recently announced a Joint Development Agreement with Houston

Pharmaceuticals to assist the Company in obtaining a license for certain

patents.

Wall Street Press Wire’s in-depth profile for Oncolin Therapeutics is

available at: http://www.wallstreetpresswire.com/page.php?BN_UID=38

The stock closed Tuesday at Forty Five cents a share.

Cell Genesys, Inc. (NASDAQ: CEGE) up 31.4% on 8.9 million shares traded.

Cell Genesys is focused on the development and commercialization of novel

biological therapies for patients with cancer.

InterMune, Inc. (NASDAQ: ITMN) up 18.5% on 7.2 million shares traded.

InterMune is a biotechnology company focused on the research, development

and commercialization of innovative therapies in pulmonology and

hepatology.

Lehman Brothers Holdings Inc. (NYSE: LEH) up 17.8% on 77 million shares

traded. Lehman Brothers, an innovator in global finance, serves the

financial needs of corporations, governments and municipalities,

institutional clients, and high net worth individuals worldwide.

Wall Street Press Wire:

Wall Street Press Wire (WSPW) is the premiere online financial destination

of choice for today’s investment community, and a leading provider of

online press release distribution and a disseminator of electronic

information. From Wall Street to Main Street, our goal is to bridge the gap

between emerging publicly traded companies and shareholders across the

country.

With many small publicly traded companies operating under the radar of

mainstream Wall Street, our service places their news story in front of the

eyes of the investment community. Utilizing a targeted distribution

approach, their story reaches the top news websites on the web and

thousands of investors nationwide. For more information on our products,

please visit: http://www.wallstreetpresswire.com/content.php?UID=5

Wall Street Press Wire (WSPW) is a division of Wall Street Capital Funding

LLC (WSCF). WSCF also maintains a contractual, working relationship with

Stock Market Alerts LLC and its Wall Street Enews brand. WSPW is not a

registered broker/dealer and may not sell, offer to sell or offer to buy

any security. WSPW profiles are not a solicitation or recommendation to

buy, sell or hold securities. An offer to buy or sell can be made only with

accompanying disclosure documents from the company offering or selling

securities and only in the states and provinces for which they are

approved. The material in this release is intended to be strictly

informational. The companies that are discussed in this release have not

approved the statements made in this release nor approved the timing of

this release. All statements and expressions are the sole opinion of WSPW

and are subject to change without notice. Information in this release is

derived from a variety of sources including that company’s publicly

disseminated information, third parties and WSPW research. The accuracy or

completeness of the information is not warranted and is only as reliable as

the sources from which it was obtained. WSPW disclaims any and all

liability as to the completeness or accuracy of the information contained

and any omissions of material fact in this release. The release may contain

technical inaccuracies or typographical errors. It is strongly recommended

that any purchase or sale decision be discussed with a financial adviser,

or a broker-dealer, or a member of any financial regulatory bodies.

Investment in the securities of the companies’ discussed in this release is

highly speculative and carries a high degree of risk. WSPW is not liable

for any investment decisions by its readers or subscribers. Investors are

cautioned that they may lose all or a portion of their investment if they

make a purchase in WSPW profiled stocks.

This profile is not without bias, and is a paid release. WSCF expects to be

compensated Twenty Two Thousand Dollars for coverage of Oncolin

Therapeutics (OTCBB: OCOL), previously known as Edgeline Holdings, Inc.

(OTCBB:ELHI), by the company, for services provided including

dissemination of company information in this release. Prior to the name and

symbol change, WSCF was previously compensated for services rendered in

2008 and 2007; the previous compensation can be viewed by looking at a

previous WSNA, ELHI press release. WSCF holds no shares of the stock. WSCF

may receive compensation for future services. Any additional compensation

will be disclosed at such time that WSCF is aware of a client’s desire to

begin services. WSCF may have received shares of a company profiled in this

release prior to the dissemination of the information in this release. WSCF

may immediately sell some or any shares in a profiled company held by WSCF

and may have previously sold shares in a profiled company held by WSCF.

WSCF’s services for a company may cause the company’s stock price to

increase, in which event WSCF would make a profit when it sells its stock

in a company. In addition, WSCF’s selling of a company’s stock may have a

negative effect on the market price of the stock.

This release contains “forward-looking statements” within the meaning of

Section 27A of the Securities Act of 1933, as amended, and Section 21E the

Securities Exchange Act of 1934, as amended and such forward-looking

statements are made pursuant to the safe harbor provisions of the Private

Securities Litigation Reform Act of 1995. “Forward-looking statements”

describe future expectations, plans, results, or strategies and are

generally preceded by words such as “may,” “future,” “plan” or “planned,”

“will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or

“projected.” You are cautioned that such statements are subject to a

multitude of risks and uncertainties that could cause future circumstances,

events, or results to differ materially from those projected in the

forward-looking statements, including the risks that actual results may

differ materially from those projected in the

forward-looking statements as a result of various factors, and other risks

identified in a company’s annual report on Form 10-K or 10-KSB and other

filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the

forward-looking statements included herein, and not place undue reliance on

such statements. The

forward-looking statements in this release are made as of the date hereof

and WSPW undertakes no obligation to update such statements